Supplement analysis backed by scientific evidence · PT

← All supplements
Strong evidenceHeart & metabolic

Red Yeast Rice

Red yeast rice genuinely lowers LDL cholesterol — because it contains monacolin K, which is chemically identical to the drug lovastatin. That also means it carries statin-like risks, with far worse dose standardisation than a prescription.

What the science says

  • Lowers LDL cholesterol Strong evidence

    A 2023 systematic review and meta-analysis of randomised controlled trials found red yeast rice reduced LDL cholesterol by roughly 25-40 mg/dL (around 15-25%) versus placebo, alongside reductions in total cholesterol and triglycerides. The effect tracks the monacolin K content: products delivering 3-10 mg/day perform like a low-dose statin, and products with negligible monacolin do essentially nothing.

  • Alternative for people who cannot tolerate statins Moderate evidence

    Trials in statin-intolerant patients show meaningful LDL reduction with acceptable tolerability in many participants, which is why it is used clinically in this niche. But the mechanism is identical to a statin, so the pharmacological reason for intolerance often persists — real muscle symptoms and enzyme elevations are reported in pharmacovigilance data.

  • Reduces cardiovascular events Limited evidence

    The main outcome evidence is the Chinese Coronary Secondary Prevention Study using a specific Xuezhikang extract, which reported fewer coronary events. This has not been replicated with Western commercial supplements, and no supplement product on the market has demonstrated event reduction in its own right.

  • Product dose is unreliable Strong evidence

    Independent analyses have repeatedly found monacolin K content in commercial products varying by more than a hundredfold between brands, plus contamination with the nephrotoxic mycotoxin citrinin in some batches. You often cannot know what dose you are actually taking.

Dosage & safety

Studied doseTrials typically used extracts supplying 3-10 mg/day of monacolin K, usually with an evening meal. Since 2022, EU regulation caps monacolin K in food supplements at under 3 mg per daily dose and bans it for pregnant, breastfeeding and over-70 populations — European products are therefore weaker than those used in older trials. Effects on LDL appear within 4-8 weeks. Choose a product that states monacolin K content and tests for citrinin.
SafetyTreat this as a low-dose statin, not a gentle herb. Reported adverse effects mirror statins: myalgia, rarely rhabdomyolysis, and liver enzyme elevations including cases of hepatotoxicity — both documented in adverse event reporting system reviews. Contraindicated in pregnancy, breastfeeding, active liver disease, and alongside a prescription statin (additive risk). Serious interactions with CYP3A4 inhibitors: grapefruit juice, clarithromycin, itraconazole, ritonavir, cyclosporine, and with fibrates. Citrinin contamination is a real quality risk. Anyone taking it should have liver enzymes and, if symptomatic, creatine kinase checked, and should tell their doctor — many people take it without disclosing it because they consider it 'natural'.

Scientific references

Where to buy

Jarrow Formulas, Red Yeast Rice + Co-Q10, 120 Veggie Capsules

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in Heart & metabolic